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Clusterin has recently been shown to act as an antiapoptotic protein that confers drug-resistance in models of
epithelial tumors. The aim of our work was to provide an insight into a possible role of clusterin in the regulation of
drug-resistance in melanoma. In tissue samples, clusterin expression was low in nevi, but high in primary me-
lanoma and melanoma metastases. Clusterin was also strongly expressed in melanoma cell lines, but was barely
detectable in cultured melanocytes. To elucidate a possible role of clusterin in drug-resistance of melanoma,
clusterin expression was regulated by either plasmid-driven overexpression or by antisense-mediated downreg-
ulation. Clusterin overexpression was associated with an increase in drug-resistance, i.e., with an increased sur-
vival of melanoma cells in the presence of cytotoxic drugs. In contrast, downregulation of clusterin by 20-O-(2-
methoxy)ethyl (20MOE)-modiﬁed antisense oligonucleotides (AS-ODN) directed against clusterin mRNA signiﬁ-
cantly reduced drug-resistance, i.e., decreased survival of melanoma cells in the presence of cytotoxic drugs. To
evaluate the effects of clusterin-antisense treatment in vivo, we applied an SCID-mouse/human-melanoma xeno-
transplantation model. Pre-treatment of mice with the 20MOE-modiﬁed clusterin AS-ODN was associated with a sig-
nificantly improved tumor response to dacarbazine as compared with animals pretreated with a scrambled control
oligonucleotide. Taken together, we show that clusterin is strongly expressed in melanoma. Downregulation of clus-
terin reduces drug-resistance, i.e., reduces melanoma cell survival in response to cytotoxic drugs in vitro and in vivo.
Thus, reducing clusterin expression may provide a novel tool to overcome drug-resistance in melanoma.
Key words: antisense oligonucleotides/apoptosis/clusterin/drug-resistance/melanoma
J Invest Dermatol 124:1300 –1307, 2005
Melanoma is a highly aggressive neoplasm that shows a
poor response to currently applied treatment regimens. The
standard cytotoxic therapy, dacarbazine, has a response
rate between 15% and 20% in the more optimistic studies
and seldomly leads to durable responses. A number of
combination therapies have also remained unsatisfactory
(Serrone et al, 2000; Tsao et al, 2004). Hence, drug-resist-
ance, defined as decreased cell death in response to a
cytotoxic therapy, is a main problem in the therapy of met-
astatic melanoma. Drug-resistance can be modulated by
increased efflux of a drug, increased metabolization/detoxi-
fication or an increased resistance of tumor cells against the
induction of apoptotic cell death by cytotoxic drugs. In me-
lanoma the latter is a major mechanism. Melanoma has a
very low intrinsic level of apoptosis and different proteins in
the apoptotic pathways can be defective by mutation or
loss of expression. Alternatively, apoptosis can be regulated
by other pathways, e.g., the regulation of Bcl-2 by ras-
activated pathways, to achieve a high antiapoptotic poten-
tial (Rockmann and Schadendorf, 2003; Soengas and
Lowe, 2003).
Clusterin is a protein widely expressed in mammalian
tissues, and is also known as testosterone repressed mes-
sage-2 (TRPM-2), sulfated glycoprotein 2 (SGP-2), or apo-
lipoprotein J (ApoJ). It was first described as a protein
isolated from ram testes fluid with the ability to ‘‘cluster’’ red
blood cells (Blaschuk et al, 1983). Clusterin is synthesized
as a primary, 60 kDa, translation product of 449 amino ac-
ids, which is cleaved into an a and b subunit. These sub-
units are subsequently linked by disulfide bridges to form an
extensively N-glycosylated, secreted, heterodimeric protein
of 76–80 kDa. The final molecular weight depends on the
degree of glycosilation, and the a and b subunits usually
appear as a smear around 40 kDa in an SDS polyacrylamide
gel. Besides the mRNA transcript that codes for the het-
erodimeric form of clusterin, a second transcript coding for
a smaller (50–55 kDa) isoform localized in the nucleus can
be generated by alternative splicing (Leskov et al, 2003).
The nuclear isoform is not cleaved into an a and b subunit or
extensively glycosylated. It was shown to be located in the
cytoplasm of MCF-7 breast carcinoma cells as an inactive
precursor that translocates into the nucleus upon irradia-
tion (Yang et al, 2000). Clusterin was implicated in tissue
Abbreviations: AS-ODN, antisense oligonucleotide; 20MOE, 20-O-
(2-methoxy)ethyl; SC-ODN, scrambled control oligonucleotide
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remodeling, lipid transport, regulation of complement lysis,
stabilization of stressed proteins, and apoptotic cell death.
A clusterin knockout mouse was fertile and had no obvious
phenotype. (Rosenberg and Silkensen, 1995; Jones and
Jomary, 2002; Trougakos and Gonos, 2002) A number of
studies marked clusterin as an antiapoptotic protein that
protects cells from diverse apoptosis-inducing stimuli like
androgen withdrawal, heat shock, oxidative stress, stimu-
lation of the CD95/Fas pathway, or treatment with ethanol
(Viard et al, 1998; Miyake et al, 2000b, 2001; Dumont et al,
2002). In experimental animal models, inflammatory myo-
cardial damage in autoimmune disease was increased in
the absence of clusterin and neuronal cell death after ex-
perimentally induced cerebral hypoxia was decreased by
overexpression of clusterin (McLaughlin et al, 2000; Wehrli
et al, 2001). In contrast, the 50 kDa nuclear isoform of clus-
terin led to growth inhibition and caspase-3-independent
cell death in MCF7 cells (Yang et al, 2000). In histological
samples taken from normal colon mucosa, colon adenoma,
and invasive colon carcinoma, a switch from preferential
expression of the nuclear to the cytoplasmic isoform of
clusterin was observed (Pucci et al, 2004).
In line with an antiapoptotic role of the heterodimeric
isoform of clusterin is the observation that high clusterin
expression was detected in various human tumors and
in vivo tumor models (Parczyk et al, 1994; Miyake et al,
2000b; Wellmann et al, 2000; Xiaodi et al, 2003). Clusterin
expression also positively correlates with increasing malig-
nancy and pathological grading of tumors in breast and
prostate cancer (Steinberg et al, 1997; Redondo et al,
2000). Clusterin was, however, also demonstrated to exhibit
growth-inhibiting effects in in vitro models of SV40 im-
mortalized or epidermal growth factor (EGF)-stimulated
prostate cells (Bettuzzi et al, 2002; Zhou et al, 2002). In
c-Myc-transfected epithelial cells, clusterin blocked carcin-
ogenesis in vivo (Thomas-Tikhonenko et al, 2004).
Based on its antiapoptotic properties, clusterin became
an interesting target for antisense oligonucleotide (AS-
ODN)-based therapeutic strategies. Downregulation of
clusterin led to decreased drug-resistance, i.e., decreased
survival of tumor cells in response to a cytotoxic therapy,
in tumor cell lines derived from prostate, kidney, and lung
cancer (Miyake et al, 2000a; Zellweger et al, 2000; July
et al, 2004). Direct comparison of a phosphorothioate-mod-
ified ODN with an additionally 20-O-(2-methoxy)ethyl
(20MOE)-modified ODN (OGX-011, OncoGenex Technolo-
gies, Vancouver, Canada) showed a higher activity and a
longer half-life of 20MOE-modified ODN (Zellweger et al,
2001). Recently, OGX-011 entered clinical phase I testing
for prostate and other clusterin-positive cancers.
The aim of our study was to find out whether clusterin is
expressed in melanoma and whether clusterin would mod-
ulate drug-resistance in melanoma cells in vitro and in vivo.
Results
Clusterin is overexpressed in human melanoma cells as
compared with melanocytes As shown in Fig 1, both the
uncleaved (60 kDa) and the b-subunit (40 kDa) of the mature
form of heterodimeric clusterin were detected in all me-
lanoma cell lines investigated, whereas they were barely
detectable in two different batches of normal human me-
lanocytes. A band correlating to the  50 kDa isoform,
described to be able to locate to the nucleus, was neither
detected using the routinely applied goat polyclonal anti-
body (Fig 1) nor with a monoclonal mouse antibody recently
shown to detect this isoform of clusterin (data not shown).
To assess the expression in clinical samples, immunohisto-
chemical staining was performed in a series of nevi, primary
melanomas, and melanoma metastases. Although a low
expression of clusterin was present in all samples, only two
of 11 nevi (18%) had a high expression of clusterin, defined
as more than two-thirds of cells staining positive for clus-
terin. In contrast, four of ten primary melanomas (40%) and
six of ten melanoma metastases (60%) exhibited a high
expression level of clusterin, indicating that expression of
clusterin increases in the course of melanoma disease pro-
gression (data not shown).
Overexpression of clusterin leads to increased drug-re-
sistance in melanoma cells Clusterin overexpression was
achieved using plasmid-driven stable transfection. Mel-
Juso cells were selected for this experiment since they dis-
played the lowest melanoma-associated expression of
clusterin (Fig 1, lane Mel-Juso). Expression of clusterin in
wild-type (Mel-Juso), vector control (Juso-Neo), and clus-
terin-overexpressing (Juso-Cl) cells was verified by western
blotting (Fig 2A). In a cytotoxicity assay, clusterin overex-
pression significantly increased resistance to cytotoxic
drugs after treatment with cisplatin or taxol. 5-fluorouracil
(5FU) was also tested but did not have an effect on Mel-
Juso cells (data not shown). Clusterin overexpression in-
creased the IC50 for cisplatin from 6 to 27 mM and the IC50
for taxol from 2 to 15 mM (Fig 2B and C). Hence, we con-
clude that clusterin overexpression protects the cells from
drug-induced cytotoxicity.
Antisense oligonucleotides (AS-ODN) efﬁciently down-
regulate clusterin and enhance sensitivity toward cyto-
static drugs If overexpression of clusterin is associated
Figure1
Clusterine Expression. (C) in two different populations of normal hu-
man melanocytes (NHEM 6083 and 2489) and four human melanoma
cell lines (518A2, 607B, Mel-Juso and SKMEL-28). 60 kDa, unproc-
essed protein. 40 kDa, b-subunit of the processed, heterodimeric pro-
tein. A polyclonal goat anti-clusterin antiserum was used for the
immunoblot. The picture depicts a longer exposure to demonstrate that
clusterin is also expressed in melanocytes.
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with an increase in drug-resistance in melanoma cells,
downregulation of clusterin should provide the opposite ef-
fect and sensitize melanoma cells to a cytotoxic treatment.
To test this idea, melanoma cells with high clusterin ex-
pression (Fig 1, lane 518A2) were treated with 20MOE-mod-
ified AS-ODN directed against clusterin. This led to a
concentration-dependent downregulation of clusterin-pro-
tein, whereas treatment with a scrambled control oligonuc-
leotide (SC-ODN) showed no effect (Fig 3A).
We were interested in knowing whether a combined
treatment of AS-ODN directed against clusterin and chem-
otherapy might decrease drug-resistance in vitro. Three dif-
ferent chemotherapeutics were used: (i) cisplatin, a drug
forming mainly G¼G inter- and intrastrand linkages, (ii)
taxol, an antimicrotubule agent, and (iii) the antimetabolite
5FU. The different time frames applied in these assays re-
flect the different mechanisms of the drugs used. In the
case of cisplatin, an IC50 of 9 mM was observed after pre-
treatment with 500 nM clusterin AS-ODN compared with an
IC50 of 32 and 39 mM, respectively, after treatment with
500 nM of SC-ODN or lipofectin alone (Fig 3B). A similar
shift in dose–response curves was achieved using a com-
bination of AS-ODN and taxol or 5FU (Fig 3C and D). Hence,
we conclude that AS-ODN treatment against clusterin sig-
nificantly reduces drug-resistance of melanoma cells, inde-
pendent of the respective cytotoxic mechanism.
Downregulation of clusterin is associated with in-
creased activation of drug-induced apoptosis We rea-
soned that the downregulation of clusterin would sensitize
melanoma cells toward the pro-apoptotic effect of cytotoxic
substances. An early marker for apoptosis is an increase in
cells exhibiting phophatidylserine on the outer leaflet of the
cell membrane that can be measured by annexin V binding.
Subsequently, these cells become permeable for DNA-
binding drugs like 7-aminoactinomycin D (7AAD) and show
reactivity for both markers (van Engeland et al, 1998; Le-
coeur et al, 2002). Since Annexin V detects early phases of
apoptotic cell death, we decided to analyze the cells 12 h
after addition of cisplatin. Downregulation of clusterin by the
AS-ODN in combination with a subsequent treatment with
10 mM of cisplatin was associated with a significant increase
in annexin V binding whereas no difference was seen in the
respective controls (Fig 4A and B). Interestingly, some cells
seemed to react with apoptosis to treatment with clusterin-
directed antisense only. (Fig 4A, lane control, lower panel
and Fig 4B).
Downregulation of clusterin enhances the response
to dacarbazine in vivo in an SCID-mouse/human-me-
lanoma xenotransplantation model To test whether the
clusterin 20MOE-AS-ODN would also influence the drug-
resistance of melanoma cells in vivo, 518A2 melanoma cells
were injected subcutaneously into the flank of SCID mice.
Antisense treatment was started after formation of an es-
tablished tumor of at least 100 mm2 tumor volume and was
performed every three days, i.p., following a loading phase
of 4 d with daily injections. Clusterin expression was re-
duced by 470% in tumor samples, 11 d after start of
treatment (23  5%) as compared with mice treated with
SC-ODN (100  15%) or saline (97  22%) (Fig 5A and B).
Downregulation of clusterin in the antisense-treated group
was observed until the end of the experiment, 3 days after
the last injection. No significant difference in tumor volume
between animals pre-treated with the clusterin AS-ODN, the
SC-ODN, or animals injected with saline alone was ob-
served (Fig 5C, inset). In contrast, AS-ODN pre-treated mice
demonstrated a reduction in tumor size by more than 85%
after a 4-d course of daily tretament with 80 mg per kg
dacarbazine. The tumors in the control groups didnot show
Figure 2
Over expression of clusterine leads to increased drug-resistence in
melanoma cells. (A) Expression of clusterin (C) in clusterin-overex-
pressing (Juso-Cl), vector-control (Juso-Neo) and wild-type Mel-Juso
cells. A polyclonal goat anti-clusterin antibody was used for the immuno-
blot. (B, C) Cytotoxicity assay with clusterin-overexpressing (Juso-Cl),
and vector-control (Juso-Neo) Mel-Juso cells. Increasing concentrations
of cisplatin or taxol were added. Cell growth was determined photo-
metrically using an MTS assay. Values shown are the relative absorption
in comparison to 0 mM of cisplatin or taxol in the respective group  SD.
Calculated IC50 are indicated in the upper right corner of each panel.
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any reduction in size at this time point and reacted to the
chemotherapy with a delay of 3–6 d (Fig 5C, large panel).
Mouse weight at the end of the in vivo experiment was not
significantly different, indicating that there was no apparent
difference in toxicity beween the treatment groups (data not
shown).
Discussion
Conflicting evidence exists with respect to clusterins role in
cell death as well as to its role in carcinogenesis and tumor
progression. Clusterin was presented to protect cells from
apoptotic stimuli in vitro, and increased cell death was seen
under some conditions in adult animals of a clusterin
knockout mouse strain (Viard et al, 1998; McLaughlin et al,
2000; Miyake et al, 2000b, 2001; Wehrli et al, 2001; Dumont
et al, 2002). The absence of clusterin was, however, also
reported to lead to a decrease in neuronal cell death after
experimentally induced cerebral hypoxia in fetal mice (Han
et al, 2001). Clusterin was demonstrated to protect tumor
cells from prostate, kidney, and lung cancer against
apoptosis (Miyake et al, 2000a; Zellweger et al, 2000; July
et al, 2004) but is also able to inhibit cell growth in tumor
cells stimulated either by addition of EGF, or cells trans-
formed by SV40 or c-myc (Bettuzzi et al, 2002; Zhou et al,
2002; Thomas-Tikhonenko et al, 2004). Although clusterin is
upregulated in renal clear cell carcinoma, in some lymph-
omas, in prostate cancer, in breast cancer, and was iden-
tified as a marker in intestinal neoplasias (Parczyk et al,
1994; Miyake et al, 2000b; Redondo et al, 2000; Wellmann
et al, 2000; Xiaodi et al, 2003), it is downregulated in tes-
ticular germ tumors (Behrens et al, 2001). This indicates that
clusterin exhibits different functions depending on the cel-
lular background and the specific situation, i.e., tumor in-
itiation versus tumor progression or fetal mice versus adult
animals.
This study was performed to investigate clusterin’s role in
melanoma.
We demonstrate that clusterin is expressed at high levels
in human melanoma. Levels of heterodimeric clusterin
in melanoma cell lines are significantly upregulated as
Figure 3
Down regulation of clusterin enhances drug sensitivity in melanoma cells. (A) 518A2 melanoma cells were pretreated with either lipofectin
alone (LF), lipofectin in combination with an antisense oligonucleotide directed against clusterin (AS), or lipofectin in combination with a scrambled
control oligonucleotide (SC) in the indicated concentrations. Protein lysates were prepared and applied onto an SDS PAGE gel. The immunoblot was
performed using a polyclonal goat anti-clusterin antiserum (middle panel, only the 60 kDa unprocessed protein is shown). Bands were analyzed
densitometrically and expressed as the relative amount of the lipofectin control. (B–D) 518A2 cells were plated in 96-well plates and pretreated with
either lipofectin alone (LF), lipofectin in combination with 500 nM AS-ODN directed against clusterin (AS), or lipofectin in combination with SC-ODN
(SC) in the indicated concentrations. Thereafter, increasing concentrations of cisplatin, taxol, or 5FU were added. Cell growth was determined
photometrically using an MTS assay. Values shown are the relative absorption in comparison with 0 mM of cisplatin, taxol, or 5-fluorouracil (5FU) in
the respective pre-treatment group  SD. Calculated IC50 are indicated in the upper right corner of each panel.
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compared with melanocytes and increased expression is
found in a higher percentage of primary melanomas and
melanoma metastases than in melanocytic nevi. Compara-
ble with our data, increased expression acording to disease
progression, was observed in breast and prostate cancer
(Steinberg et al, 1997; Redondo et al, 2000).
We further demonstrate that clusterin modulates drug-
resistance in melanoma cell lines.
We show that overexpression of clusterin leads to an
increase in resistance to cisplatin and taxol in melanoma
cells with a low endogenous level of clusterin. Downregu-
lation of clusterin by AS-ODN reduced the IC50 for cisplatin,
taxol, and 5FU. This demonstrates that the effect achieved
by the regulation of clusterin must be due to an influence on
a common pathway activated by all of these different cyto-
toxic substances. An increase in apoptotic cell death as
shown by an increase of cells staining positive for annexin V
was observed after combined treatment with AS-ODN and
Figure 4
Down regulation of clusterine increases drug induced apoptosis.
(A) 518A2 melanoma cells were pretreated with either lipofectin alone
(LF), lipofectin in combination with 500 nM of an antisense oligonuc-
leotide directed against clusterin (AS) or lipofectin in combination with
500 nM of scrambled control oligonucleotide (SC). After treatment, cells
were stained with FITC-labeled annexin V and 7-aminoactinomycin D
(7AAD). Subsequently, cells were analyzed by fluorescence-activated
cell sorter (FACS). Numbers of annexin V positive (lower right) or an-
nexin V/7AAD double positive (upper right) cells are given as % of
events gated at the side of the charts. The experiment represents one
of three that gave comparable results. (B) Results from the experimen-
tal protocol described in Fig 5A. Bars represent the mean number of
annexin V positive cells from three independent experiments in
%þSD. Groups were compared by a paired t test and the respective
p-values are indicated.
Figure5
SCID-mouse human-melanoam xenotransplantation model. Mice
with established tumors grown after s.c. injection of 518A2 melanoma
cells were pre-treated with either 10 mg per kg clusterin antisense
oligonucleotide, scrambled control oligonucleotide, or saline. Eleven
days after start of treatment animals received 80 mg per kg of da-
carbazine over 4 d. (A) Western blot for clusterin tumor in lysates at
days 23 and 33. (B) Clusterin levels from three tumors per treatment
group at day 11. Bands were analyzed densitometrically, normalized to
the b-actin control, and depicted as % of SC-ODN. A mouse mono-
clonal antibody against clusterin was used for the immunoblot. Bars
represent SD. (C) Mean tumor volume throughout the experiment.
Control groups without dacarbazine treatment are shown in the insert.
Bars represent SD. ‘‘’’ represents differences statistically significant by
Student’s t test (po0.05).
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cisplatin. Hence, we conclude that clusterin regulates drug-
resistance of melanoma cells by influencing drug-induced
apoptosis. A smaller increase in annexin V staining was also
observed after antisense-treatment alone in vitro, whereas
no significant difference in tumor size between antisense-
treated animals and animals treated with the SC-ODN with-
out the addition of dacarbazine was seen.
The mechanism underlying clusterin’s regulation of
apoptosis is not yet clarified. The expression of an isoform
of clusterin that is able to translocate to the nucleus and
upon doing so exerts pro-apoptotic functions, is, as men-
tioned in the introduction, one possibility (Yang et al, 2000;
Leskov et al, 2003). We did not detect this 50 kDA isoform in
melanocytes or melanoma cells. Although a switch from
expression of the nuclear isoform to expression of the het-
erodimeric isoform of clusterin was observed to be asso-
ciated with the progression from colon adenoma to colon
carcinoma (Pucci et al, 2004), we did not detect such a
difference between melanocytic nevi and melanoma sam-
ples. In an osteosarcoma cell line, downregulation of Bcl-2
was found to be associated with RNAi-mediated downreg-
ulation of clusterin (Trougakos et al, 2004). We did not
observe Bcl-2 regualtion after antisense-mediated down-
regualtion of clusterin in melanoma cells (data not shown).
AS-ODN, chemically modified stretches of single-strand-
ed DNA, are pharmacologically potent inhibitors of disease-
related protein expression (Jansen and Zangemeister-Wittke,
2002). They are designed to bind to their complementary
mRNA sequence once they get inside the cell, thereby in-
hibiting expression of the encoded protein (Myers and Dean,
2000). 20MOE-modified AS-ODN have the advantage of in-
creased stability and a longer half-life as compared with
earlier generations of antisense molecules. Therefore they
can be applied up to only once a week and are still as ef-
fective as conventional AS-ODN with a phosphorothioate
backbone (Zellweger et al, 2001). We applied clusterin AS-
ODN every 3 d, i.p., in an SCID-mouse/human-melanoma
xenotransplantation model and observed a downregulation
of clusterin in the tumor. This was associated with a signif-
icantly improved tumor response to dacarbazine as shown
by a reduction of tumor size by more than 80% only 4 d after
the initiation of cytostatic treatment. Control treated animals
did not show any reaction at this time point and did only
react with a delay of about 6 d.
Our data identify clusterin as a protein capable of reg-
ulating apoptosis and drug-resistance in model systems of
human melanoma in vitro and in vivo. Together with data on
the expression of clusterin in clinical samples of metastatic
melanoma, this provides a basis for the further development
of strategies downregulating clusterin to a clinically appli-
cable therapeutic modality for patients suffering from me-
lanoma.
Materials and Methods
Tumor cell lines 518A2, 607B (courtesy of Dr Peter Schrier, Lei-
den, the Netherlands), SKMEL28 (ATCC), and Mel-Juso (German
Collection of Microorganisms and Cell Culture, DSMZ, Bra-
unschweig, Germany) melanoma cells were maintained in DMEM
(Invitrogen, Carlsbad, California) supplemented with 8% heat-
inactivated FCS. 500 mg per mL Geneticin (Invitrogen) was used for
selection of transfectants. Normal human epidermal melanocytes
(NHEM) were obtained as cryopreserved cells from Clonetics/
Cambrex (East Rutherford, New Jersey). NHEM were maintained in
MBM-2 medium supplemented with the MGM-3 bullet kit (all
Clonetics) and were used between the third and sixth doubling after
thawing. For experiments comparing melanocytes and melanoma
cells, all cells were cultured in DMEM with 8% FCS for 24 h.
Generation of transfected Mel-Juso cells The human clusterin
cDNA containing mammalian expression vector pRc/CMV was
kindly provided by Dr Martin Gleave (Vancouver, Canada). Cells
were transfected using a cationic lipid (Lipofectin, Invitrogen) ac-
cording to the manufacturer’s instruction. 500 mg per mL Geneticin
(Invitrogen) was used for clonal selection of transfected cells. In-
dividual clones were tested for clusterin expression by western
blotting. To avoid subcloning artifacts, clones were pooled and
used as a ‘‘mass culture’’ in the cytotoxicity assays.
Clusterin oligodesoxynucleotides 20MOE-modified ODN’s used
in this study were provided free of charge by OncoGenex Tech-
nologies (Vancouver, Canada). The sequence of the AS-ODN is
CAGCAGCAGAGTCTTCATCAT (OGX-011); the sequence of the
SC-ODN is CAGCGCTGACAACAGTTTCAT.
Treatment of cells with ODN  chemotherapy Lipofectin (In-
vitrogen) was used to increase the ODN uptake of cells. Cells were
treated for 4 h on two consecutive days with ODN in the indicated
concentration in serum-free OPTIMEM (Invitrogen) containing 4 mg
per mL of Lipofectin. After this time, the medium was replaced with
standard culture medium as described above. Chemotherapeutic
agents included cisplatin, taxol, and 5FU and were added 24 h
after pretreatment with the respective oligonucleotides. Cisplatin,
taxol, and 5FU were obtained from the pharmacy at the university
hospital.
Western blotting Samples were prepared using a buffer contain-
ing 150 mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% SDS,
50 mM Tris, 2 mM PMSF, 2 mM Na3O4V, and complete protease
inhibitors (Roche Diagnostics, Basel, Switzerland). Western blots
were performed using 30 mg of protein. Prior to application, protein
lysates were cooked at 951C for 10 min in equal volumes of a 2 
loading buffer (30 mM Tris, 12.5% glycerol, 1% SDS, 12.2 mM
mercaptoethanol, 0.05% bromophenol blue). Ponceau-red stain
and an antibody directed against b-actin or vinculin were used
as loading controls. Antibodies used were: anti-clusterin goat
polyclonal (Santa Cruz Biotechnology, Santa Cruz, California),
anti-clusterin mouse monoclonal (Lot 41D, Upstate, Charlottesville,
Virginia) (used to control for expression of the 50 kDa nuclear iso-
form of clusterin), and anti-actin rabbit polyclonal (Sigma, St Louis,
Missouri).
Immunohistochemistry 4 mm thick, paraffin-embedded tissue
sections were deparaffinated using xylol and an ethanol dilution
series. Melanin was bleached by incubation in 1% sodium nitrate
and 2% sodium bisulfite. Antigen retrieval was performed by
cooking in citrate buffer and endogenous peroxidase was blocked
by incubation with 3% hydrogen peroxide. After incubation in
blocking serum, slides were incubated with an anti-clusterin rabbit
polyclonal antibody (Santa Cruz Biotechnology) at a dilution of
1:100. A rabbit isotype antibody was used as negative control.
Staining was performed using the LSAB kit (DAKO, Glostrup, Den-
mark). The experiments using human material were approved by
the local ethics committee.
Cytotoxicity assays The influence of AS-ODN treatment or over-
expression of clusterin on chemosensitivity was assessed using an
MTS-assay system (Cell Titer 96, Promega, Madison, Wisconsin).
This assay measures the activity of dehydrogenase enzymes,
which is roughly equivalent to the number of viable cells. Briefly,
2  104 cells per well were seeded in 96-well culture plates and
allowed to adhere overnight. ODN treatment experiments were
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performed as described above. Cells were then treated with var-
ious concentrations of cisplatin, taxol, or 5FU. After the indicated
times, cell titer 96 reagent was added and cells were incubated at
361C for 2 h. The absorbance was determined using a microtiter
plate reader (Wallac/Perkin Elmer, Wellesley, Massachusetts). Ab-
sorbance values were normalized for the respective control and
expressed as thee relative amount of enzyme activity. The controls
used were cells from the same pre-treatment group without ad-
dition of the respective cytotoxic substance measured at the same
time point.
Fluorescence-activated cell sorter (FACS) analysis 105 cells
were seeded in 60 mm culture wells and treated with ODN as
described above. Subsequently, cells were trypsinized, washed
two times in PBS, and resuspended in a buffer containing 10 mM
HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4. Cells were then
incubated with FITC-labeled annexin V (Bender Medsystems,
Vienna, Austria) for 5 min and subsequently coincubated with 1 mg
per mL 7AAD (Sigma) for another 10 min. Labeled cells were
analyzed on a FACScan (BD Biosciences, San Jose, California)
with an argon laser at 488 nm.
SCID-mouse/human-melanoma xenotransplantation mod-
el 10106 518A2 melanoma cells were injected subcutaneously
into the flank of female CB17 SCID mice (Charles River Labora-
tories, Wilmington, Massachusetts). Twelve days after injection
when tumors 410 mm in diameter had formed, animals were ran-
domized in groups. They received either 10 mg per kg clusterin-
20MOE AS-ODN, 10 mg per kg scrambled oligonucleotide in
200 mL of 0.9% saline, or saline alone by i.p. injection. Animals
were injected daily from day 12 to 15 and every third day thereafter
until the end of the experiment. On day 23, tumors from each group
were harvested for analysis of clusterin expression. On days
23–26, animals received daily i.p. injections of dacarbazine at a
concentration of 80 mg per kg. Tumor size was measured by a
caliper and tumor volume was calculated by the formula: [(largest
diameter in mm)  (smallest diameter in mm)2]  p/6.
Treatment groups consisted of 14 animals in the antisense- and
scrambled-oligonucleotide groups and of seven animals in the sa-
line groups. The protocol was approved by the local animal welfare
committee.
All experiments except the in vivo experiment were independ-
ently performed at least three times.
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